T-DXd has been approved for various types of previously treated advanced or recurrent cancers (HER2-positive breast and gastric cancer, HER2-low breast cancer, and HER2-mutated non-small cell lung cancer). Here, ERBB2 is linked to non-small cell lung carcinoma.